PARP2

Across TCGA pan-cancer cohorts, PARP2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PARP2 data layer compared with 27 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher PARP2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PARP2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

LSCC, PDAC, and CCRCC are the cancer types where PARP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.894	0.484	<.001	36	view →
PDAC	DFS	Tertile	All	0.811	0.706	.020	8	view →
CCRCC	DFS	Median	All	0.877	0.652	.015	3	view →
HNSC	DFS	Quartile	II,III,IV	1.000	0.924	.042	2	view →
LUAD	DFS	Tertile	II,III,IV	0.964	0.698	.019	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PARP2–LSCC (DFS)

Open the LSCC breakdown →